Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing
08:00am, Wednesday, 08'th Oct 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River &Toxys announce collaboration to validate use of ReproTracker®, an in vitro alternative for developmental & reproductive toxicolo
Why Charles River Stock May Struggle In Its Final Phase
07:22am, Tuesday, 07'th Oct 2025
Charles River Laboratories International Inc. (NYSE:CRL) is entering a critical point in its 18-phase Adhishthana cycle. The stock currently sits in Phase 17 on the weekly chart, with Phase 18, its fi
Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026
03:51pm, Monday, 29'th Sep 2025
Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non
Charles River Laboratories Announces Chief Financial Officer Transition
07:05am, Tuesday, 16'th Sep 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Chief Financial Officer Transition.
CRL Stock Rises Following New Strategic Oncology Collaborations
09:46am, Friday, 12'th Sep 2025
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River collaborates to enhance oncology manufacturing portfolio by advancing development of cell and gene therapies to treat cancer.
Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript)
12:40pm, Wednesday, 10'th Sep 2025
Charles River Laboratories International, Inc. (NYSE:CRL ) Baird 2025 Global Healthcare Conference September 10, 2025 9:40 AM EDT Company Participants James Foster - Chairman, President & CEO Conferen
Charles River Laboratories International, Inc. (NYSE:CRL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants James Foster - Chairman, Presiden
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
08:00am, Monday, 08'th Sep 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Baird and Morgan Stanley Conferences.
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
09:51am, Thursday, 04'th Sep 2025
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Charles River Stock May Benefit From Joining EASYGEN Consortium
11:26am, Monday, 01'st Sep 2025
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing
08:00am, Tuesday, 26'th Aug 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .
Interpreting Charles River (CRL) International Revenue Trends
10:15am, Monday, 11'th Aug 2025
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
01:30pm, Wednesday, 06'th Aug 2025
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing
12:50pm, Wednesday, 06'th Aug 2025
Charles River Laboratories International Inc. CRL stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.
